Retrospective Study
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Jun 15, 2022; 13(6): 454-465
Published online Jun 15, 2022. doi: 10.4239/wjd.v13.i6.454
Immediate-release tofacitinib reduces insulin resistance in non-diabetic active rheumatoid arthritis patients: A single-center retrospective study
Chrong-Reen Wang, Hung-Wen Tsai
Chrong-Reen Wang, Department of Internal Medicine, National Cheng Kung University Hospital, Tainan 70403, Taiwan
Hung-Wen Tsai, Department of Pathology, National Cheng Kung University Hospital, Tainan 70403, Taiwan
Author contributions: Wang CR designed the report, collected the clinical data, and wrote the paper; Wang CR and Tsai HW analyzed the clinical data.
Institutional review board statement: This study was approved by the Ethics Committee of National Cheng Kung University Hospital, No. B-ER-105-108.
Informed consent statement: The Institutional Review Board waived the requirement of informed consent from each patient due to the study being classified as a retrospective review of medical records.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: The data of this study can be provided to researchers by the corresponding author upon reasonable request.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Chrong-Reen Wang, MD, PhD, Full Professor, Department of Internal Medicine, National Cheng Kung University Hospital, No. 138 Sheng-Li Road, Tainan 70403, Taiwan. wangcr@mail.ncku.edu.tw
Received: January 14, 2022
Peer-review started: January 14, 2022
First decision: April 18, 2022
Revised: April 18, 2022
Accepted: May 28, 2022
Article in press: May 28, 2022
Published online: June 15, 2022
Core Tip

Core Tip: An increased risk of insulin resistance (IR) has been identified in rheumatoid arthritis (RA), a chronic inflammatory disorder with elevated levels of pathogenic cytokines. In addition to controlling RA activity, biologics targeting proinflammatory cytokines have been shown to reduce IR, while it remains to be elucidated whether Janus kinase inhibitor therapy can cause IR reduction in such patients. This retrospective study carried out in non-diabetic active RA patients classified into high-IR and low-IR groups before tofacitinib (TOF) therapy demonstrated reduced IR by 24 wk of TOF treatment in the active RA patients with high baseline IR status.